Pharmaceutical Sector Faces 'Bubble Effect' Risk Due to Weight Loss Drug Growth, Report Finds
A Deloitte report highlights that the pharmaceutical sector is at risk of a 'bubble effect' due to the rapid growth of weight loss and diabetes drugs, which have driven R&D returns to 7% for the top 20 pharma companies. This growth has shifted the focus from oncology, which is no longer the largest contributor to late-stage pipeline value. However, the report warns that this surge masks a weaker overall industry environment.
Topics: Deloitte report GLP-1 drugs obesity treatments oncology pharmaceutical R&D